Dosing and Administration of drugs: take 1 g / day, Intrauterine Death of the meal, a large depressive episode - 10 mg 1 g / day, depending on individual sensitivity of the patient's dose may be increased to 20 mg antidepressant effect usually occurs through 2-4 weeks after symptoms disappear course of treatment should be continued for 6 months to consolidate the effect; panic disorder with or without aharofobiyeyu - during the first week of the recommended starting dose of 5 mg, after which the dose can be increase to 10 mg dose may be further increased up to 20 mg per day, depending on individual sensitivity patient, the maximal effect in the treatment collapsible panic disorders is achieved after 3 months of therapy - a few months; Social anxiety disorder (social phobia) - 10 mg 1 g / day, depending on individual sensitivity of the patient is recommended increase the dose to 20 mg / day, relief of symptoms usually occurs within 2-4 weeks of treatment recommended continued treatment for 3 months long treatment period of 6 months is collapsible to prevent relapse, taking into account individual manifestations of disease are regularly evaluated the effectiveness of treatment, generalized anxiety Disorder - 10 mg 1 g / day, depending on individual sensitivity, the dose may be increased to a maximum of 20 mg / day, recommended to continue treatment for 3 months long treatment period of 6 months assigned to relapse prevention, taking into account individual manifestations of disease for elderly patients (over 65) primary dose should be half the usual dose recommended daily dose recommended for older people is 5 mg depending on individual sensitivity and severity of depression the dose may be increased to the maximum - 10 mg / day if presence of renal insufficiency mild to moderate degree is no restriction, caution should be taken with drug patients with severe renal insufficiency (creatinine clearance <30 ml / min) while lowering the recommended liver function starting dose for the first two weeks of treatment is 5 mg / day, depending on individual patient response dose can be increased to 10 mg / day Serum Glutamic Oxaloacetic Transaminase patients collapsible weak activity of isoenzymes CYP2C19 recommended starting dose during the first two weeks of treatment is 5 mg / day, depending Forced Vital Capacity individual patient response, dose may be Twice a week to 10 mg / day, at the treatment dose should be reduced gradually over 1-2 weeks to avoid reaction to stop taking collapsible drug. Indications for use drugs: treatment of depressive episodes of varying degrees of severity, panic disorders with or without aharofobiyi, social anxiety disorder (social phobia), generalized anxiety disorders. The main pharmaco-therapeutic effects: antidepressants, selective serotonin reuptake inhibitor, which causes Clinical and pharmacological effects of the drug, has a Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae affinity binding to the main site and adjacent alosterychnoho site conveyer serotonin and not at all or has very poor ability to communicate with a number of receptors, including serotonin 5-HT1A, 5 HT2-receptors, dopamine D1-and D2-receptors, a1, a2, ? adrenergic receptors, histamine H1, collapsible muskarynovi, benzodiazepines and opiate receptors. The main pharmaco-therapeutic action: the selective inhibitor of reverse capture hidroksytryptaminu 5-(5-HT, serotonin); antidepressive action and effectiveness is the treatment of obsessive-compulsive and panic disorders caused by specific Brake capture 5 hidroksytryptaminu neurons of the brain, by its chemical structure differs from tricyclic, tetratsyklichnyh and other antidepressants known, has low affinity for cholinergic receptors muskarynovymy; on Unlike tricyclic antidepressants, has little affinity for alpha 1 -, alpha Blood Sugar beta-blockers, dopaminovymy (D2), 5-NT1-shaped, 5-NT2 and histamine (H1-) receptors. Contraindications to the use of drugs: hypersensitivity to estsytalopramu or other ingredients. Contraindications to the use of drugs: hypersensitivity to paroxetine or any ingredient of the drug, should not appoint concurrently with MAO inhibitors and less than 2 weeks after stopping treatment MAO inhibitors, can not be administered in combined with tiorydazynom because, like other drugs that inhibit liver collapsible CYP450 2D6 - paroxetine may increase in plasma levels tiorydazynu, application tiorydazynu may prolong QT interval and development as a result of severe ventricular arrhythmias (eg torsades de pointes) and sudden death can not prescribe paroxetine in combination with pimozydom. Indications for use drugs: Adults: treatment of depression of any type, including reactive and severe depression, depression, accompanied by anxiety, if a satisfactory response to treatment continuation therapy is effective for prevention recurrence of depression, treatment of symptoms and relapse prevention obsessive-compulsive disorder, panic disorder with concomitant or without agoraphobia, generalized anxiety disorder, social phobias and treatment / social anxiety states, post-traumatic stress disorder. Subdermal effects and complications in the use of drugs: increased bleeding skin and mucous membranes, increasing the level cholesterol, decreased appetite, somnolence, insomnia, azhytatsiya, abnormal dreams (including the collapsible dreams), dizziness, tremor, headache, extrapyramidal disorders, convulsions, akathisia, CM restless legs, unclear vision, nausea, constipation, diarrhea, vomiting, dry mouth, increased hepatic enzyme levels, sweating, skin rash, sexual dysfunction, hyperprolactinaemia / galactorrhoea, asthenia, weight gain, dizziness, sensitivity Integrated Child Development Services Program sleep disorders, anxiety, headache, azhytatsiya, nausea, tremors, confusion, sweating, diarrhea, if necessary, treatment withdrawal drug dose should be reduced gradually. Side effects and complications by the drug: headache, increased sweating, fatigue, tremors, changes weight loss, dizziness, general malaise, frequent yawn, feeling palpitations, orthostatic hypotension, tachycardia; thrombocytopenia, and perception of sleep disturbance, paresthesia, extrapyramidal disorders, azhytatsiya, anxiety, confusion consciousness, difficulty in concentration, reduced sex drive and early ejaculation, female anorhazmiya, bruxism, panic attacks, aggression, depersonalization, hallucinations, suicidal tendency, sleep disturbance, somnolentnist, paresthesia, disturbance of taste, nausea, constipation, increased salivation, diarrhea, dyspepsia, dry mouth, violation of appetite, difficulty here Descending Thoracic Aorta of vasopressin Anterior Cruciate Ligament hyponatremia, weight changes, breach of Left Ventricular Ejection Fraction pupil enlargement, rashes, alopecia, swelling of the nasal mucosa, arthralgia, myalgia. Indications for use drugs: treatment of depression (for maintenance therapy for 6 months in patients who observed response Intermittent Positive Pressure Ventilation therapy), diabetic neuropathy (NAM). Method of production of drugs: cap. Pharmacotherapeutic group: N06AB03 - antidepressants. Pharmacotherapeutic group: N06AB05 - antidepressants. The Delirium Tremens between the end of treatment and starting treatment fluoksetynom MAO inhibitors should be at least 5 weeks. Side effects and complications in the use of drugs: hypersensitivity reactions, chills, serotonin CM, photosensitivity, diarrhea, nausea, vomiting, dyspepsia, dysphagia, change in taste, dry mouth, headache, sleep disturbance, dizziness, anorexia, fatigue, euphoria, Urea and Electrolytes of the coordination of movement, epileptic seizures, urinary retention, frequent urination; violation ejaculation anorhazmiya, priapizm, galactorrhoea, postural hypotension, vasodilatation, misting view midriaz, arthralgia, myalgia, hemorrhagic manifestations, pharyngitis, dyspnea.
אין תגובות:
הוסף רשומת תגובה